Mannose-6-Phosphate Receptor: A Target for Theranostics of Prostate Cancer

The development of personalized and non‐invasive cancer therapies based on new targets combined with nanodevices is a major challenge in nanomedicine. In this work, the over‐expression of a membrane lectin, the cation‐independent mannose 6‐phosphate receptor (M6PR), was specifically demonstrated in...

Full description

Saved in:
Bibliographic Details
Published inAngewandte Chemie Vol. 127; no. 20; pp. 6050 - 6054
Main Authors Vaillant, Ophélie, Cheikh, Khaled El, Warther, David, Brevet, David, Maynadier, Marie, Bouffard, Elise, Salgues, Frédéric, Jeanjean, Audrey, Puche, Pierre, Mazerolles, Catherine, Maillard, Philippe, Mongin, Olivier, Blanchard-Desce, Mireille, Raehm, Laurence, Rébillard, Xavier, Durand, Jean-Olivier, Gary-Bobo, Magali, Morère, Alain, Garcia, Marcel
Format Journal Article
LanguageEnglish
German
Published Weinheim WILEY-VCH Verlag 11.05.2015
WILEY‐VCH Verlag
Wiley Subscription Services, Inc
Subjects
Biotechnology
Cancer
Cations
Chemistry
Kohlenhydrate
Krebs
Lectins
Nanoparticles
Nanopartikel
Nanostructure
Patients
Prostate
Prostate cancer
Receptors
Rezeptoren
Syntheseplanung
Therapy
Online AccessGet full text

Cover

More Information
Summary:The development of personalized and non‐invasive cancer therapies based on new targets combined with nanodevices is a major challenge in nanomedicine. In this work, the over‐expression of a membrane lectin, the cation‐independent mannose 6‐phosphate receptor (M6PR), was specifically demonstrated in prostate cancer cell lines and tissues. To efficiently target this lectin a mannose‐6‐phosphate analogue was synthesized in six steps and grafted onto the surface of functionalized mesoporous silica nanoparticles (MSNs). These MSNs were used for in vitro and ex vivo photodynamic therapy to treat prostate cancer cell lines and primary cell cultures prepared from patient biopsies. The results demonstrated the efficiency of M6PR targeting for prostate cancer theranostic. Treffsicher: Für einen Mannose‐6‐phosphat‐Rezeptor wurde Überexpression in Prostatagewebe und Krebszelllinien nachgewiesen. Auf den Rezeptor wurde mit einem auf mesoporösen Silikananopartikeln (MSNs) befestigten M6P‐Analogon gezielt. MSNs sind effiziente Trägermaterialien für die Krebserkennung und ‐therapie, und M6PR als Target hat Potenzial für die Theranostik von Prostatakrebs.
Bibliography:ArticleID:ANGE201500286
ark:/67375/WNG-KXPV2JD1-X
Financial support from CNRS, ANR P2N - NanoptPDT, and BQR University of Montpellier 1 grant is gratefully acknowledged. The fellowship for O.V. was supported by the Ligue Nationale Contre le Cancer. We gratefully thank Montpellier RIO imaging platform. Support from FEDER région Languedoc Roussillon, project No. 41470 is gratefully acknowledged.
CNRS
istex:41AA6D250F073414660AFAEF3CA523174693E351
FEDER - No. 41470
Financial support from CNRS, ANR P2N ‐ NanoptPDT, and BQR University of Montpellier 1 grant is gratefully acknowledged. The fellowship for O.V. was supported by the Ligue Nationale Contre le Cancer. We gratefully thank Montpellier RIO imaging platform. Support from FEDER région Languedoc Roussillon, project No. 41470 is gratefully acknowledged.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0044-8249
1521-3757
DOI:10.1002/ange.201500286